Table 4.
The 40 Most Significant Probe Sets (ranked by P value) From the List of Differentially Expressed Probe Sets Between Patients With Alveolar RMS RLND Positive and Negative Disease
| Gene Name | Gene Symbol | Mean FD | P (ttest) |
|---|---|---|---|
| Apolipoprotein E | APOE | 1.7 | < .001 |
| Apolipoprotein E | APOE | 1.6 | < .001 |
| β2-microglobulin | B2M | 2.2 | < .001 |
| Complement component 1, q subcomponent, A chain | C1QA | 1.8 | < .001 |
| Complement component 1, r subcomponent | C1R | 1.6 | < .001 |
| Complement component 1, s subcomponent | C1S | 1.8 | < .001 |
| Complement component 7 | C7 | 2.1 | < .001 |
| Calcium channel, voltage-dependent, P/Q type, α1A subunit | CACNA1A | −1.6 | < .001 |
| CD74 molecule, major histocompatibility complex, class II invariant chain | CD74 | 2.3 | < .001 |
| Carboxypeptidase E | CPE | 1.8 | < .001 |
| GTP binding protein overexpressed in skeletal muscle | GEM | 1.7 | < .001 |
| Major histocompatibility complex, class I, A | HLA-A | 1.9 | < .001 |
| Major histocompatibility complex, class I, A | HLA-A | 2.4 | < .001 |
| Major histocompatibility complex, class I, B | HLA-B | 2.6 | < .001 |
| Major histocompatibility complex, class I, B | HLA-B | 2.4 | < .001 |
| Major histocompatibility complex, class I, C | HLA-C | 2.6 | < .001 |
| Major histocompatibility complex, class I, C | HLA-C | 2.4 | < .001 |
| Major histocompatibility complex, class I, C | HLA-C | 2.3 | < .001 |
| Major histocompatibility complex, class II, DM α | HLA-DMA | 1.5 | < .001 |
| Major histocompatibility complex, class II, DP α1 | HLA-DPA1 | 2.1 | < .001 |
| Major histocompatibility complex, class II, DP α1 | HLA-DPA1 | 2.5 | < .001 |
| Major histocompatibility complex, class II, DP β1 | HLA-DPB1 | 2.0 | < .001 |
| Major histocompatibility complex, class II, DQ β1 | HLA-DQB1 | 1.6 | < .001 |
| Major histocompatibility complex, class II, DR α | HLA-DRA | 2.2 | < .001 |
| Major histocompatibility complex, class II, DR α | HLA-DRA | 2.2 | < .001 |
| Major histocompatibility complex, class II, DR β1 | HLA-DRB1 | 2.2 | < .001 |
| Major histocompatibility complex, class II, DR β1 | HLA-DRB1 | 2.2 | < .001 |
| Major histocompatibility complex, class II, DR β1 | HLA-DRB1 | 2.0 | < .001 |
| Major histocompatibility complex, class II, DR β1 | HLA-DRB1 | 2.5 | < .001 |
| Major histocompatibility complex, class I, F | HLA-F | 1.8 | < .001 |
| Insulin-like growth factor binding protein 7 | IGFBP7 | 2.3 | < .001 |
| Immunoglobulin heavy locus | IGH@ | 6.0 | < .001 |
| Immunoglobulin κ locus | IGK@ | 2.4 | < .001 |
| Immunoglobulin κ constant | IGKC | 2.0 | < .001 |
| Immunoglobulin κ constant | IGKC | 3.7 | < .001 |
| Immunoglobulin κ constant | IGKC | 4.0 | < .001 |
| Immunoglobulin κ variable 1D-13 | IGKV1D-13 | 1.5 | < .001 |
| Immunoglobulin λ locus | IGL@ | 4.8 | < .001 |
| Immunoglobulin λ-like polypeptide 3 | IGLL3 | 1.7 | < .001 |
| Interleukin-6 signal transducer (gp130, oncostatin M receptor) | IL6ST | 1.8 | < .001 |
Abbreviations: RMS, rhabdomyosarcoma; RLND, regional lymph node disease; FD, fold difference.
*
Relative to patients who are RLND positive.